Exploratory study to investigate biomarkers associated with pathogenesis of infantile hemangioma.

Exploratory study to investigate biomarkers associated with pathogenesis of infantile hemangioma. - Exploratory study to investigate biomarkers associated with pathogenesis of infantile hemangioma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038574

Enrollment

Registered

2019-11-13

Start date

2019-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile hemangioma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Infantile hemangioma patients aged 2 weeks to 2 months with informed consent from the legally representative. 2) Patients who have not been treated for infantile hemangioma before the study.

Exclusion criteria

Exclusion criteria: 1) Internal type 2) Patients who need to start treatment of infantile hemangioma before proliferating phase and the initiation of study. 3) Patients taking medications that may affect infantile hemangioma pathology and levels of biomarker before the study 4) Patients suspected of serious complications and diseases that greatly affect cytokine levels through interview by the doctors (PHACE syndrome, infection and inflammatory diseases, etc).

Design outcomes

Primary

Measure	Time frame
Volume of infantile hemangioma in proliferating phase.	—

Countries

Japan

Contacts

Public ContactMasatoshi Jinnin

Wakayama Medical University Department of Dermatology

mjin@wakayama-med.ac.jp073-447-2300

Outcome results